Connecticut
-
FDA Refuses to Review Biohaven Drug for Rare Neuromuscular Disease With No Treatments
Biohaven’s bid to bring to market the first drug for rare neuromuscular disorder spinocerebellar ataxia has hit a setback. The FDA is refusing to review the drug’s application, a decision that could indicate the agency wants another clinical trial.
-
Biohaven drug fails another clinical test, this time in rare neuromuscular disorder
Biohaven’s migraine drug research led to an FDA-approved product with strong commercial uptake, but its other neuroscience efforts have yet to achieve the same outcomes. Drug candidate troriluzole has failed a Phase 3 test in neuromuscular disorder spinocerebellar ataxia, the molecule’s third failure in a pivotal study in the past two years.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Pfizer buys its way into migraine with $11.6B Biohaven Pharma acquisition
Pfizer is turning to M&A to get its next blockbuster, buying Biohaven six months after the two companies began a commercialization pact centered on the oral migraine drug Nurtec. The acquisition will lead to the spinout of Biohaven’s other assets into a new, publicly traded company capitalized with $275 million.
-
Biohaven migraine drug partnered with Pfizer lands twin European approvals
The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for Biohaven, it’s also a win for Pfizer, which holds rights to commercialize the drug outside of the U.S.
-
Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med
Neuroscience drug developer Biohaven Pharmaceuticals is expanding its pipeline to include epilepsy and spinal muscular atrophy. The drug developer is acquiring Channel Bioscience and licensing global rights to a Phase 3-ready drug from Bristol Myers Squibb.
-
Biohaven’s migraine progress pays off with a Pfizer marketing pact for two drugs
Biohaven Pharmaceuticals has seen strong U.S. market uptake for its oral migraine drug, Nurtec. With regulatory decisions looming around the world, the company has landed the marketing muscle of Pfizer, which is paying $500 million up front for the right to market that drug and another clinical-stage compound outside of the U.S.
-
Specialty physicians in Connecticut gain path to value-based care, payment boost via private health plan
The State of Connecticut Health Plan is the first commercial plan in the country to have its episodes-of-care payment model designated as an Advanced APM by CMS. With limited Advanced APM options via CMS, this designation will provide specialty physicians in the state a path to value-based care payments through the private sector.
-
Biohaven drug licensed from AstraZeneca fails Phase 3 test in rare neuro disorder
Biohaven’s bet on an AstraZeneca drug for multiple system atrophy does not pan out, failing a pivotal study in the rare, neurodegenerative disorder. But a separate Phase 3 study evaluating verdiperstat in amyotrophic lateral sclerosis is still moving forward.
-
FDA approves first drug for severe itching in chronic kidney disease patients
Chronic kidney disease patients who experience pruritus after dialysis can now get relief from the first FDA-approved treatment for the condition. Cara Therapeutics received the FDA’s green light for its injectable drug, Korsuva.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug
Arvinas’ early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1 billion to share in the development and commercialization of this therapy.
-
Billing software startup Inbox Health raises $15M
Medical payments platform Inbox Health raised $15 million in series A funding. The company works with third-party billing companies to better communicate with patients and make bills clearer.
-
IQVIA pays Quest Diagnostics $760M to get full control of central lab joint venture
IQVIA has acquired Quest Diagnostics’ minority stake in Q2 Solutions, a central laboratory services joint venture the two companies formed in 2015. But Quest will remain a preferred provider of lab testing services under an agreement with Q2.
-
Melinta antibiotic for MRSA & other serious skin infections wins FDA approval
Melinta Therapeutics already sells an antibiotic for serious skin infections. But FDA approval of Kimyrsa gives clinicians another option to offer patients, one with more convenient dosing.
-
Stamford Health wants to vaccinate 3,000 people a day. Here’s how.
Stamford Health has partnered with city and state officials and community organizations to execute its Covid-19 vaccine administration plans. The health system has ambitious plans to vaccinate 3,000 people a day, with a focus on health equity.
-
Purdue to plead guilty, pay $8.3B deal to resolve opioid charges
In addition to monetary damages and the guilty pleas, the government is seeking to transform the maker of OxyContin into a public benefit company that would fund efforts to curb opioid abuse and give away drugs to prevent overdose deaths.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
